Why SPRAVATO®
If you’ve taken two or more oral antidepressants and still experience symptoms of depression, you might have treatment-resistant depression (TRD).
SPRAVATO®, the only FDA-approved nasal spray for adult patients with two forms of challenging-to-treat major depressive disorder (MDD):
- Adults with MDD who’ve had an inadequate response to two or more oral antidepressants, known as treatment-resistant depression (TRD)
- Depressive symptoms in adults with MDD with suicidal thoughts or actions (MDSI)
Getting Started on SPRAVATO®
If you have treatment-resistant depression (TRD), you may benefit from adding SPRAVATO® to your current oral antidepressant.
Proven Effective for Treatment-Resistant Depression
You may benefit from adding SPRAVATO® to your existing oral antidepressant if you’re an adult with major depressive disorder (MDD) who has had an inadequate response to two or more oral antidepressants, known as treatment-resistant depression (TRD).
SPRAVATO® Clinical Study
Adults with treatment-resistant depression who were part of a clinical study were given either a nasal esketamine spray or a placebo spray.
Those who added esketamine, the active ingredient in SPRAVATO®, to their oral antidepressant experienced a greater reduction of depressive symptoms at four weeks compared to those who received placebo plus an oral antidepressant.*
*Based on an overall score on a standardized rating scale.